Q-omics provides the consensus-scored PRPF38B profile across patient tissues and cancer cell-line models. PRPF38B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRPF38B is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, PRPF38B protein abundance shows 25,839 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, STAD, and GBM as cancer lineages where PRPF38B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF38B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF38B survival associations across molecular data types. PRPF38B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF38B RNA expression–survival associations across cancer types. High PRPF38B expression shows unfavorable associations in KIRP, LIHC, ACC, LGG and KICH, but favorable associations in BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRPF38B RNA expression.
This table summarizes PRPF38B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRPF38B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF38B shows lower tumor expression in THCA and higher tumor expression in STAD, LIHC, HNSC, KIRC and CHOL. The STAD box plot shows higher PRPF38B RNA expression in tumor versus normal tissue (log2 FC = +0.822, t-test p < 0.001).
This table shows molecular features associated with PRPF38B in patient tissues and cancer cell lines. In patient samples, PRPF38B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRPF38B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
